文献速递前列腺癌

磁共振成像引导经尿道超声消融治疗前列腺癌的12个月结局

Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer.
PubMed 文献 · J Urol · 2020-10-06

TACT研究是一项前瞻性多中心试验,纳入115例 favourable 至 intermediate 风险前列腺癌患者,行全腺体消融并保留尿道和尖部括约肌。12个月时96%患者PSA下降≥75%,中位PSA下降95%,65%活检无癌,3级不良事件发生率8%。

要点

  • 全腺体消融保留尿道和括约肌,中位治疗时间51分钟,热覆盖98%。
  • 96%患者达到PSA下降≥75%的主要终点,中位PSA下降95%。
  • 12个月活检65%无癌,3级不良事件发生率8%。

核心结论

  • MRI引导经尿道超声全腺体消融对局限性前列腺癌可实现有效组织消融和PSA下降,毒性及残留病变率低。

研究设计与样本

  • 前瞻性多中心试验(TACT),纳入13个中心115例 favourable 至 intermediate 风险前列腺癌男性,行全腺体消融保留尿道和尖部括约肌。

主要发现

  • 72例(63%)为Grade Group 2,77例(67%)为NCCN intermediate 风险。
  • 中位治疗时间51分钟,靶体积热覆盖98%(IQR 95-99),空间消融精度±1.4 mm。
  • 9例(8%)发生3级不良事件,110/115例(96%)达到PSA下降≥75%的主要终点,中位PSA下降95%,PSA nadir 0.34 ng/ml。
  • 中位前列腺体积从37 cc降至3 cc,68例 pretreatment Grade Group 2 中52例(79%)12个月活检无Grade Group 2。
  • 111例有12个月活检数据者中72例(65%)无癌证据;92例中69例(75%)维持或恢复勃起(IIEF问题2评分≥2)。

关键数值与推荐

  • 12个月持续Grade Group 2的多变量预测因素包括筛查时前列腺内钙化、MRI热覆盖靶体积不理想及12个月MRI PI-RADS≥3病灶(p<0.05)。

临床怎么用

  • 对于 favourable 至 intermediate 风险局限性前列腺癌,MRI引导经尿道超声全腺体消融可作为保留尿道和括约肌的消融选项,需关注钙化及热覆盖不足对残留风险的影响。

局限性

  • 原文未报告随访超过12个月的数据、随机对照比较及长期肿瘤学结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Magnetic resonance imaging-guided transurethral ultrasound ablation uses directional thermal ultrasound under magnetic resonance imaging thermometry feedback control for prostatic ablation. We report 12-month outcomes from a prospective multicenter trial (TACT). MATERIALS AND METHODS: A total of 115 men with favorable to intermediate risk prostate cancer across 13 centers were treated with whole gland ablation sparing the urethra and apical sphincter. The co-primary 12-month endpoints were safety and efficacy. RESULTS: In all, 72 (63%) had grade group 2 and 77 (67%) had NCCN® intermediate risk disease. Median treatment delivery time was 51 minutes with 98% (IQR 95-99) thermal coverage of target volume and spatial ablation precision of ±1.4 mm on magnetic resonance imaging thermometry. Grade 3 adverse events occurred in 9 (8%) men. The primary endpoint (U.S. Food and Drug Administration mandated) of prostate specific antigen reduction ≥75% was achieved in 110 of 115 (96%) with median prostate specific antigen reduction of 95% and nadir of 0.34 ng/ml. Median prostate volume decreased from 37 to 3 cc. Among 68 men with pretreatment grade group 2 disease, 52 (79%) were free of grade group 2 disease on 12-month biopsy. Of 111 men with 12-month biopsy data, 72 (65%) had no evidence of cancer. Erections (International Index of Erectile Function question 2 score 2 or greater) were maintained/regained in 69 of 92 (75%). Multivariate predictors of persistent grade group 2 at 12 months included intraprostatic calcifications at screening, suboptimal magnetic resonance imaging thermal coverage of target volume and a PI-RADS™ 3 or greater lesion at 12-month magnetic resonance imaging (p <0.05). CONCLUSIONS: The TACT study of magnetic resonance imaging-guided transurethral ultrasound whole gland ablation in men with localized prostate cancer demonstrated effective tissue ablation and prostate specific antigen reduction with low rates of toxicity and residual disease.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Klotz L, Pavlovich CP, Chin J, et al. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. J Urol. 2020. PMID: 33021440. doi:10.1097/JU.0000000000001362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。